HK/China Healthcare Analyst (ex-Fosun Pharma)

Xinyao (Criss) Wang

Over 13 years' experience in both finance and healthcare, covering clinic operations, investment and equity research in both China and overseas.

China Healthcare Weekly (Aug.5) - HK IPO, Innovent, BeiGene, the Largest IVD Centralized Procurement

Will the Approval of Genuine Biotech's COVID-19 Oral Drug Change China's Zero-COVID Policy?

China Healthcare Weekly (Aug.12)-AI Drug Discovery, License-In Mode Valuation, Pet Medical Equipment

Pre-IPO Best Wellness Innovation Group - Here Are the Concerns

Pre-IPO Lepu Medical Technology - Lepu Is in a Difficult Position and Turning It Around Takes Time

Pre-IPO Shanghai Chicmax Cosmetic - The Current Development Strategy Will Not Go Far

Gravity Works As WeWork Doesn't; Now Plan B

Equity Capital Markets

Cali Biosciences / Equity Capital Markets

<ul>
<li>Both the postoperative pain management and the expansive application of anesthetics in various fields would increase the market demand for ropivacaine.</li>
<li>
<a href="https://www.smartkarma.com/entities/cali-biosciences-co-ltd" target="_blank" data-smartkarma-citation="entities:35539:1" rel="noopener">Cali Biosciences (CALI HK)</a>’s core product, the ropivacaine long-acting analgesic injection drug candidate CPL-01, would have to face the challenges of fierce competition, uncertain market acceptance, and negative policy impact.</li>
<li>Together with other concerns such as slow development progress, “not rich enough” pipeline and potential liquidity risk, we are conservative about Cali’s outlook at the current stage.  </li>
</ul>


Both the postoperative pain management and the expansive application of anesthetics in various fields would increase the market demand for ropivacaine.

Cali Biosciences (CALI HK)’s core product, the ropivacaine long-acting analgesic injection drug candidate CPL-01, would have to face the challenges of fierce competition, uncertain market acceptance, and negative policy impact.
Together with other concerns such as slow development progress, “not rich enough” pipeline and potential liquidity risk, we are conservative about Cali’s outlook at the current stage.  


Pre-IPO Cali Biosciences - The Industry, the Business and the Concerns